Currently, many studies on neuropsychiatric disorders have utilized massive trio-based whole-exome sequencing (WES) and whole-genome sequencing (WGS) to identify numerous de novo mutations (DNMs). Here, we retrieved 17 104 DNMs from 3555 trios across four neuropsychiatric disorders: autism spectrum disorder, epileptic encephalopathy, intellectual disability and schizophrenia, in addition to unaffected siblings (control), from 36 studies by WES/WGS. After eliminating non-exonic variants, we focused on 3334 exonic DNMs for evaluation of their association with these diseases. Our results revealed a higher prevalence of DNMs in the probands of all four disorders compared with the one in the controls (P o 1.3 × 10 − 7 ). The elevated DNM frequency is dominated by loss-of-function/deleterious single-nucleotide variants and frameshift indels (that is, extreme mutations, P o 4.5 × 10 − 5 ). With extensive annotation of these 'extreme' mutations, we prioritized 764 candidate genes in these four disorders. A combined analysis of Gene Ontology, microRNA targets and transcription factor targets revealed shared biological process and non-coding regulatory elements of candidate genes in the pathology of neuropsychiatric disorders. In addition, weighted gene co-expression network analysis of human laminar-specific neocortical expression data showed that candidate genes are convergent on eight shared modules with specific layer enrichment and biological process features. Furthermore, we identified that 53 candidate genes are associated with more than one disorder (Po0.000001), suggesting a possibly shared genetic etiology underlying these disorders. Particularly, DNMs of the SCN2A gene are frequently occurred across all four disorders. Finally, we constructed a freely available NPdenovo database, which provides a comprehensive catalog of the DNMs identified in neuropsychiatric disorders.
INTRODUCTION
Over the last decade, next-generation sequencing has become one of the most effective tools for identifying the genetic causes of Mendelian, complex and undiagnosed diseases. [1] [2] [3] Recent whole-exome sequencing (WES) and whole-genome sequencing (WGS) studies of neuropsychiatric disorders have indicated that de novo mutations (DNMs) have prominent roles in these disorders [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] despite their high heritabilities and genetic heterogeneities. 21, 22 DNMs including single-nucleotide variants (SNVs), small insertions and deletions (indels), copy-number variants and structural variants are extremely rare and regarded as more deleterious, having a stronger disruptive effect on biological functions due to less stringent evolutionary selection. 23, 24 Therefore, DNMs offer considerable insights into the genetic bases and clinical interpretations of sporadic cases in which inheritance seems to offer no explanation for disease etiology. 7, 10, 25 Trio-based WES/WGS is revolutionizing the identification of DNMs, and has been performed on 43000 controls and patients with neuropsychiatric disorders, mostly including autism spectrum disorder (ASD), epileptic encephalopathy (EE), intellectual disability (ID) and schizophrenia (SCZ). These studies identified several dozen candidate genes harboring recurrent lossof-function (LoF) DNMs that are crucial to pathogenesis of these disorders, such as CHD8, SCN2A, NTNG1 and KATNAL2 in ASD, [11] [12] [13] [14] 26, 27 GABRB3, ALG13 and CACNA1A in EE, 9 DYNC1H1, STXBP1, SYNGAP1 and SCN2A in ID, 16, 17 and LAMA2, DPYD, TRRAP and VPS39 in SCZ. 18, 19 However, the genetic etiologies of these disorders remain difficult to decipher due to limited sample sizes, high genetic heterogeneity and complex pathogenesis. 10, 22 In addition, DNMs are so rare; it has been difficult to be statistically evaluated in terms of the relevance of most detected DNMs to these diseases. To facilitate DNM interpretation, we curated and cataloged all DNMs reported to date in ASD, EE, ID, SCZ and unaffected siblings or controls by WES/WGS. We subjected all DNMs to consistent quality control standards to characterize the frequency of different classes of DNMs and prioritized genes associated with each disorder. Functional enrichment and co-expression network analysis revealed that some genetic etiologies are shared among these four neuropsychiatric disorders. In addition, the developed NPdenovo database here is a useful tool for future studies in elucidating the mechanisms and underlying the genetic etiologies of these diseases.
MATERIALS AND METHODS

Data collection and annotation
In total, 3555 trios from four disorders (ASD, EE, ID and SCZ) together with the unaffected siblings/controls were collected from currently available trios-based WES/WGS studies, in which 17 104 DNMs were identified (Figure 1 and Supplementary Table 1 ). Comprehensive annotation of DNMs were performed by ANNOVAR 28 based on RefSeq gene (hg19, from UCSC (http://genome.ucsc.edu/)), including (1) gene information (gene region, effect, mRNA GenBank accession number, amino acid change, cytoband, et al.); (2) functional prediction for missense mutations by 12 bioinformatics tools; (3) allele frequency in different populations of public database (different version of dbSNP, 1000 Genomes, ESP6500 and CG69); (4) disease-related database (ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/), HGMD (http://www.hgmd.cf.ac.uk/), COSMIC (http://cancer.sanger.ac.uk/ cancergenome/projects/cosmic/), MGI, OMIM (http://www.ncbi.nlm.nih. gov/omim)); and (5) genome features for non-coding variations (segmental duplication, VISTA enhancer, transcription factor (TF), DNase I hypersensitivity, chromatin state segmentation and non-coding RNA from ENCODE (https://www.encodeproject.org/)).
Identification of extreme mutations
To identify the pathogenic mutations, firstly, we removed all DNMs with minor allele frequency 40.1% in dbSNP138, 1000 Genome (released in April 2012), and ESP6500. Synonymous and non-frameshift mutations were eliminated due to their low possibility to contribute to disorders. The LoF mutations, such as nonsense/splicing SNVs and frameshift indels, were directly considered to be damaging. For missense mutations, which account for the majority of DNMs, though many tools or methods were developed to predict degree of damages based on evolutionary conservation or functional disruption, all of them have inevitable limitations and biases. A proposed solution for this is to use consensus prediction or majority vote of many methods. 29 Consequently, 12 generic tools and methods were applied for functional prediction of damaging missense mutations, expected with more robust statistical power than any single tool, including SIFT, 30 Polyphen2_hvar, 31 Polyphen2_hdiv, 31 MutationTaster, 32 MutationAssessor, 33 LRT, 34 FATHMM, 35 GERP++, 36 PhyloP, 37 SiPhy, 38, 39 RadialSVM and MetaLR. The predicted damaging scores of 12 tools were sourced from dbNSFP 2.0 database 29 and integrated in ANNOVAR. Then, for each missense mutation, total damaging score is the summed number of tools predicted to be 'deleterious' or 'conserved'. As missense mutations in cases were found to be more likely to have higher damaging scores (⩾8) compared with controls, only the DNMs with a damaging score higher than eight are considered to be deleterious mutations (Supplementary Figure 1) . The genes harboring rare LoF/deleterious SNVs and rare frameshift indels, which we refer to as extreme mutations, were used for candidate genes prioritization ( Figure 1 ).
Prioritize candidate genes
Our recently developed TADA program (Transmission And De novo Association), 40 which can predict risk genes accurately on the basis of allele frequencies, gene-specific penetrance and mutation rate was used to calculate the P-value for the likelihood of each gene contributing to the corresponding disorders with default parameters. To gain a clear view on risk genes in each disorder, according to the P-value generated by the TADA program, we classified genes into five different types in each disorder: 'strong' (P TADA ⩽ 0.0001), 'suggestive' (0.0001o P TADA ⩽ 0.001), 'positive' (0.001oP TADA ⩽ 0.01), 'possible' (0.01o P TADA ⩽ 0.05) and 'negative' (P TADA 40.05). Genes with P TADA ⩽ 0.05 (that is, candidate genes) were used for the analysis of functional enrichment and neocortical expression profiles ( Figure 1 ).
Neocortical expression profiles
Human laser micro-dissection data of four prenatal brains (15-21 postconceptual weeks) from BrainSpan Atlas (http://brainspan.org) 41 were used to investigate the expression patterns of candidate genes. 42 In this data, neocortex was divided into~25 areas in each sample, delineating nine layers per area from subpial granular zone to ventricular zone, corresponding to 526 neocortical samples (Supplementary Table 2 ). In this study, signed hybrid-weighted gene co-expression network analysis was performed across all neocortical samples 42 using the standard method with the power of four (as it was the smallest threshold that resulted in a scale-free R 2 fit of 0.9; Figure 1 ). 
Functional enrichment analysis
WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) was employed to perform functional enrichment analysis of candidate genes for features including Gene Ontology, TF targets, microRNA targets, KEGG pathways. 43 
RESULTS
To characterize the DNMs in neuropsychiatric disorders, we retrieved 17 104 DNMs identified from trio-based WES/WGS from ASD, EE, ID, SCZ and normal controls of 36 studies (Supplementary Table 1 ). After eliminating non-exonic variants, 3334 exonic DNMs located in the coding DNA sequence regions were left, comprising 3112 de novo SNVs and 222 de novo indels.
High prevalence of extreme DNMs in neuropsychiatric disorders
Although several studies have documented that cases have a significant high rate of LoF DNMs related to controls, 11-14 they have not presented statistically compelling evidence due to the absence of a large sample set. With the combined data from 3555 trios, we observed that disease groups have higher prevalence of DNMs (both de novo SNVs and de novo indels) compared with controls (two-sample Poisson rate test: ASD, odds ratio (OR) = 1.36, corrected P = 5.36 × 10 − 10 ; EE, OR = 1.52, P = 2.84 × 10 − 9 ; ID, OR = 1.60, P = 1.52 × 10 − 9 ; SCZ, OR = 1.31, P = 1.3 × 10 − 7 ; Table 1 and Supplementary Figure 2A) . Interestingly, we found that the significant increase of DNMs is dominated by LoF/deleterious SNVs and frameshift indels, rather than synonymous SNVs, tolerant missense and non-frameshift indels (Table 1 and Supplementary Figure 2B and E). In addition, the frequency of extreme mutations in cases and controls showed significant difference (two-sample Poisson rate test: ASD, OR = 1.80, adjusted P = 5.96 × 10 ; Table 1 and Supplementary Figure 2F ), suggesting that these extreme DNMs are likely contributed to the pathogenesis of these four neuropsychiatric disorders.
Prioritization of candidate genes Using the TADA program, 44 we identified a total of 764 potential candidate genes with P TADA ⩽ 0.05 in four disorders: 330 genes for ASD, 109 for EE, 106 for ID and 277 for SCZ (Table 2 and  Supplementary Table 3) . We identified six genes with strong associations in ASD, nine genes in EE, 18 genes in ID and seven genes in SCZ (P TADA ⩽ 0.0001), most of which harbor recurrent extreme DNMs. Many of the 764 candidate genes have been previously reported to be severely implicated in neuropsychiatric Table 4 ). Although neuropsychiatric disorders have complex etiologies and are genetically heterogeneous, the overlaps suggested that some biological processes share in to all four neuropsychiatric disorders (such as nervous system development and multicellular organismal signaling), indicating shared molecular pathologies may underlie this subtype of complex diseases. In addition, our results showed that candidate genes in each disorder are highly enriched in respective biological processes. For example, the terms transmission of nerve impulse, synaptic transmission and ion transport are over-represented in the set of EE genes.
Candidate genes that converge on these functional pathways from the neuropsychiatric disorders suggest that they are likely regulated by common special regulatory elements in their non-coding regions. Thus, we performed enrichment analysis of TFs and miR targets, which regulates the 5ʹ-upstream promoter region and downstream regulatory region (3ʹ-UTR), respectively (Supplementary Table 4 ). Interestingly, we found that several TF binding sites and miR target sites of candidate genes are shared among four neuropsychiatric disorders. For instance, the TF binding sites, 'hsa_GGGAGGRR_V$MAZ_Q6' and 'hsa_CAGGTG_V $E12_Q6' are shared by all four disorders; the miR target sites, 'hsa_TTGCACT' and 'hsa_TGAATGT' are shared by ASD and SCZ. In addition, each of the disorders was enriched with some special regulatory elements. For example, ID genes showed enrichment in the 'hsa_AAGCCAT' site (P = 2.71 × 10 − 12 , OR = 3.9), which is the target of miR-29A, miR-29B and miR-29C. It should be noted that brain-specific knockdown of miR-29 was found to result in neuronal cell death. 45 Our analysis thus demonstrated a plausible link between given TFs or miRs with these disorders, although the specific factors/miRs remain to be identified and verified. Table 2 ). The four samples correspond to the four high-quality mid-gestational brains, two from 15 and 16 pcw (post-conceptual weeks) and two from 21 pcw. White, low expression; red, high expression. (c) The distribution of candidate genes and their biological processes in four disorders (ASD, EE, ID and SCZ). Candidate genes in each module are shown as a pie chart in four disorders. The size of each pie chart is proportional to the number of genes in corresponding modules. The enrichment analysis of GO was performed by WebGestalt. ASD, autism spectrum disorder; CPo, outer cortical plate; CPi, inner cortical plate; EE, epileptic encephalopathy; ID, intellectual disability; SCZ, schizophrenia; SV, subpial granular zone; VZ, ventricular zone; WGCNA, weighted gene co-expression network analysis.
Shared neocortical expression profiles Human brain development involves complex regulation of cellular proliferation, signaling and transcription pathways, and requires orchestration of many relevant genes. 46 We performed weighted gene co-expression network analysis with our candidate genes in all 526 laminar neocortical samples (Supplementary Materials and Methods). The identified co-expression network includes eight modules of varying sizes from 36 to 170 genes with highly coordinated spatio-temporal expression patterns of each module in the human neocortex (M1-M8, Figure 2a) . All the modules consist of candidate genes of all four disorders, each is presented with laminar-specific enrichment (Figure 2b and Supplementary  Table 5 ) and distinct biological processes (Figure 2c and Supplementary Table 6 Figure 3D ) and SCZ (P = 0.31, Supplementary Figure 3E) . And the extreme DNM-containing genes in the controls was also not significantly overlapped with the 53 shared genes in the four disorders (P = 0.12, Supplementary Figure 3F) . Furthermore, these 53 shared genes are significantly enriched in several neural function-associated GO terms, such as 'regulation of transmission of nerve impulse', 'regulation of excitatory postsynaptic membrane potential' and 'regulation of neurological system process' (Supplementary Table 7 and Supplementary Table  8) . Briefly, we found that 34% of shared genes (18 of 53) are included in the largest co-expression module M1 (hypergeometric test, P = 0.026), suggesting that these shared genes may account for the common etiology of all four neuropsychiatric disorders (Figure 2a, Supplementary Table 5) .
More interestingly, different extreme DNMs of SCN2A were frequently identified in all four disorders, including five extreme DNMs in ASD (P TADA = 1.51 × 10 − 8 ), five in ID (P TADA = 8.26 × 10
), four in EE (P TADA = 4.72 × 10
) and one in SCZ (P TADA = 0.0047; Figure 3b and Supplementary Table 9 ). Of the 15 extreme mutations, 9 are frameshift indels, stop-gain or splicing site SNVs (that is, LoF DNMs), compared with zero rare LoF mutations of SCN2A in the ESP6500 database and controls (minor allele frequency o 0.01%, Supplementary Table 9 ). It is known that SCN2A encodes the α-subunit of the voltage-gated sodium channel, which is responsible for generation and propagation of action potentials in excitable cells, such as nerve and neuroendocrine cells. SCN2A and its homologs such as SCN1A and SCN8A, have been found to be associated with ASD, ID, ataxia and elevated sensitivity to pain. 47 In support of those previous discoveries, in the combined neocortex co-expression network, SCN2A was included in the largest module M1. This means that SCN2A is widely expressed in cortex, and is enriched in the intermediate zone (outer cortical plate; inner cortical plate; subplate zone; Supplementary Figure 4) . These observations suggested that SCN2A may involve common molecular pathways and contribute to overlapped phenotypes in these four disorders.
Moreover, we found that MYH9, LRP1 and POGZ were shared by ASD, ID and SCZ; GRIN2B and STXBP1 were shared by ASD, EE and ID (Figure 3b) . Several other candidate genes are shared by two disorders, such as CHD8, RELN and NRXN1 shared by ASD and SCZ; SETBP1, SETD5, BRD3, CTNNBP2, LRP2 and SLC6A1 shared by ASD and ID, WDR45, IQSEC2, CHD2, KCNQ3 and SCN8A shared by EE and ID, respectively (Figure 3b ). Despite the apparently distinct pathogenesis of these four neuropsychiatric disorders, functional association of these overlapping genes suggests that these disorders share some genetic architecture and molecular pathway features (Supplementary Table 8 ). For example, GRIN2B (glutamate receptor, ionotropic, N-methyl D-aspartate 2B) is involved in synaptic transmission and its mutations have been reported in patients with West syndrome and intellectual disability, or behavioral phenotypes.
48 SETBP1 (SET Binding Protein 1) is associated with ASD (c.2716delC, p.P906fs, P TADA = 0.004) and ID (c.1774A4T, p.K592X, P TADA = 0.0009). A recent study of more than 30 000 cases with developmental delay showed that SETBP1 is frequently mutated (both de novo SNVs/indels and de novo copynumber variants) in patients with intellectual disability and loss of expressive language. 49 The NPdenovo database To make our findings easily accessible to the research community, we have developed the NPdenovo database (http://122.228.158. 106/NPdenovo/) for storage and retrieval of DNMs, candidate genes, and their brain expression patterns, and for exploring the genetic etiology of neuropsychiatric disorders (Supplementary Figure 5 and Supplementary Materials and Methods).
DISCUSSION
To gain insight into the biological implication of DNMs in diseases, data sets from multiple independent studies need to be integratively analyzed in a comprehensive source. 7, 50, 51 In doing so, we found that extreme mutations in the four neuropsychiatric disorders are significantly more frequent than in controls. Specially, EE and ID patients are more likely to harbor recurrent DNMs than ASD and SCZ, suggesting that ID and EE have lower heterogeneities than ASD and SCZ. 7 Numerous studies have revealed that patients with recurrent mutations are prone to present with similar clinically recognizable phenotypes. 8, [52] [53] [54] Thus, the identified recurrent DNMs may provide a 'genotype-first' approach for complex diseasesubtype diagnosis and therapy. 55 For example, patients with disruptive CHD8 (chromodomain helicase DNA binding protein 8) mutations were characterized as a subtype of autism with macrocephaly, distinct faces and gastrointestinal complaints, responsible for 0.4% (15/3730) of the patients with developmental delay or ASD.
56 ADNP (activity-dependent neuroprotector) is another ASD-associated gene, which is frequently mutated in 0.17% (10/5776) of ASD cases with shared clinical phenotypes of intellectual disability and facial dysmorphisms. 57 Next, by employing the TADA program 40 to prioritize associated genes, we identified 764 genes with P TADA o0.05, of which many were previously identified candidate genes as well as a large number of novel candidate genes. Although most of these candidate genes have not been verified or validated by in vitro experiments or animal models, our analysis provided meaningful reference and a downsized list of candidate genes for further studies of these DNMs in neuropsychiatric disorders. For example, SUV420H1 (suppressor of variegation 4-20 homolog 1) was found to harbor two damaging missense mutations (p.W264S and p.A513V) and one splicing site SNV (c.977+1G4A) in unrelated ASD cases, and was thus prioritized by this study as a strong candidate gene for ASD (P TADA = 0.00009). Furthermore, two damaging de novo missense mutations (p.Q264P and p.I228S) in DEAF1 (DEAF1 TF) were described in two independent ID studies. DEAF1 is expressed in the neurons and is associated with anxiety and depression phenotypes and behavioral problems. 58, 59 In fact, numerous candidate genes harboring only one extreme DNM were identified with significant P-values. Additional experimental data may be required to determine their pathogenic role due to the heterogeneities in these disorders. For example, a dopamine transporter gene, SLC6A3 (solute carrier family 6 member 3), showed a significant P-value (P TADA = 0.01). A recent study demonstrated that the de novo extreme mutation in this gene (c.1067C4T, p.T356M) can confer risk for ASD based on animal model. 60 Therefore, candidate genes from our study provide new avenue to build up etiological network of these complex neuropsychiatric disorder.
Recently, several studies documented that LoF DNMs in ASD are often involved in chromatin remodeling, wnt signaling, transcriptional regulation and synaptic function. [25] [26] [27] Besides, activitydependent neuronal signaling networks 61 and disruption of neuroplasticity 62 also have a key role in the etiology of ASD.
Moreover, DNMs in SCZ have been implicated in its etiological development in the fetal prefrontal cortical network 20 and synaptic networks. 19 GO analysis in this study revealed that candidate genes in each disorder are enriched for some unique biological processes, but some are obviously shared, suggesting the overlapped molecular pathways in neuropsychiatric disorders. Our study provides a global view on the molecular etiologies of DNMs in neuropsychiatric disorders.
More importantly, some special regulatory elements are enriched in candidate genes. These elements include not only upstream control regions regulated by particular TFs, but also downstream regulatory regions mediated by particular miRs. Most previous studies have focused on the biological function of genes in coding regions. Given by the facts that mutations in non-coding regulatory regions are also involved in etiology of human diseases, 63, 64 regulation in non-coding regions is particularly important for brain development 44, 65 and neuropsychiatric disorders, 66, 67 we strongly propose that DNMs located in TF and miR target sites may participate in the pathology of these four disorders.
To investigate the underlying relationship between these disorders, we performed weighted gene co-expression network analysis on the 764 candidate genes and identified eight modules with the similar expression patterns in prenatal human neocortex, each module representing specific GO biological processes. Previous studies have demonstrated that ASD 51, 68, 69 and SCZ 20 genes display specific co-expression networks in the human brain or neocortex. Our analysis showed that at least eight co-expression networks of candidate genes are associated with neuropsychiatric disorders. Some of these display superficial layer enrichment or intermediate layer enrichment consistent with previous studies. 68, 69 Others display extreme high/medial/lowexpression profiles in whole neocortex or deep layer enrichment, which has not been detected in previous studies. However, no single module clearly represents an individual disorder, supporting the existence of interconnected molecular pathways in these four disorders. 7, 70, 71 This assumption is also consistent with the results of a previous protein-protein interaction analysis. 72 Previous studies have identified numerous genes associated with multiple neuropsychiatric diseases, such as SCN2A, GRIN2B, STXBP1, GABRB3, RELN, GABRA1 and MECP2. A recent trio-based WES study found that DNMs associated with chromatin modeling in SCZ (CHD8, MECP2 and HUWE1) overlap with ASD and ID. 73 In this study, we identified 53 genes that overlapped in all four disorders, support a genetic overlap between these diseases. 7, 70, 71 Only the extreme DNMs of SCN2A were identified in all four disorders. Based on our analysis, SCN2A is responsible for 0.5% (5/1038) of patients with ASD, 1.4% (4/291) of EE, 2.3% (5/220) of ID and 0.1% (1/1024) of SCZ, making it one of the most frequently mutated genes in these neuropsychiatric disorders.
In summary, we have provided new insights into the shared genetic basis of DNMs in neuropsychiatric disorders. We also provide new evidence that some candidate genes, molecular pathways, regulatory elements and expression profiles are shared among ASD, EE, ID and SCZ (Supplementary Table 10 ). All these data can be easily discovered from our online NPdenovo database. In conclusion, our findings may improve understanding of their genetic etiology and facilitate the diagnosis and genetic counseling of these disorders in the future.
